A new analysis of 19 studies involving nearly 2,000 people with non-small cell lung cancer (NSCLC) suggests that a protein in the blood, called soluble PD-L1 (sPD-L1), could help predict how long patients live without their cancer getting worse. The study found that patients with lower levels of sPD-L1 at the start of treatment had longer progression-free survival and overall survival. Specifically, those with lower sPD-L1 had a 2.26 times lower risk of their cancer progressing and a 2.04 times lower risk of dying, compared to those with higher levels. The results were highly statistically significant.
However, this is an observational finding, not a cause-and-effect proof. The studies included varied in design and treatment approaches, which could affect the results. The researchers identified a median cutoff of 90 pg/mL for sPD-L1 as a potential benchmark, but more research is needed to confirm this.
No safety concerns were reported in this analysis, as it focused on blood levels rather than a treatment. The main takeaway is that sPD-L1 is a promising biomarker, but it is not yet ready for routine use in the clinic. Patients should discuss any questions about biomarkers with their oncologist.
This research adds to the growing field of personalized medicine, where blood tests may one day help tailor treatments for lung cancer. For now, it remains an area of active investigation.
